RCS - OptiBiotix Health - Manufacturing agreement with KAG Industries

OptiBiotix HealthAnnouncement

30/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240430:nRSd4745Ma&default-theme=true

RNS Number : 4745M  OptiBiotix Health PLC  30 April 2024

OptiBiotix Health plc

("OptiBiotix" or the "Company")

 

Manufacturing agreement with KAG Industries

Supply of Slimbiome® in India as a finished product

 

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing
compounds to tackle obesity, high cholesterol, diabetes and skincare,
announces that its wholly owned Indian subsidiary, OptiBiotix Health India
Private Limited ("OHI"), has signed a manufacturing agreement with KAG
Industries ("KAG") for the supply of Slimbiome® containing products ready for
sale. KAG have developed five flavours unique to the Indian market which will
be sold by OHI to Dr Morepen, a well-known brand in India, launched in 2001 to
encourage customers to be in charge of their own health and wellbeing.

 

KAG is a specialised contract manufacturer of nutritional powders with its own
research and development laboratories allowing it to create customised
finished products for its clients. These include well known international
companies like Unilever and well known and trusted Indian brands like Apollo
and Dr Morepen. These clients require a high level of food industry
accreditation including HACCP, GMP, FSSC 22000 certification. Zeon
Lifesciences Ltd will manufacture and supply the SlimBiome® in Dr Morepen
products, creating a local manufacturing and sales base for ingredient and
finished product.  This would not be possible without having a physical
presence in India.

 

With a population of 1.4 billion people and obesity prevalence at 40.3%
(https://journals.sagepub.com/doi/full/10.1177/0972753120987465
(https://journals.sagepub.com/doi/full/10.1177/0972753120987465) ), India is a
market of strategic importance to OptiBiotix. The middle-class population in
India is expected to reach 475 million by 2030. Currently most middle-class
consumers live in the European Union (EU) and the United States, but over the
next decade, the majority will shift heavily toward India, with one in four
global middle-class consumers expected to reside in India by 2035
(https://www.asianstudies.org/publications/eaa/archives/the-middle-class-in-india-from-1947-to-the-present-and-beyond/
(https://www.asianstudies.org/publications/eaa/archives/the-middle-class-in-india-from-1947-to-the-present-and-beyond/)
) representing a significant growth opportunity.

 

The appointment of KAG brings another well respected and established provider
into the supply chain within India.

 

Stephen O'Hara, CEO of OptiBiotix, commented: "We are pleased to announce this
agreement with KAG to support the launch of SlimBiome® containing products
with Dr Morepen, a well-known and trusted supplier to pharmacies, physicians,
and retail customers across India.  We look forward to the upcoming launch of
products across India with Dr Morepen and our manufacturing partners."

 

Anuj Agarwal, Chairman & Managing Director of KAG Industries, commented:
"Dr Morepen boasts a rich legacy of over three decades, renowned for its
expertise in developing reliable health products tailored for the Indian
market. The collaboration between KAG, OHI and Dr Morepen signifies a
promising endeavour, aiming to create mutually beneficial outcomes for all
involved parties."

 

The Directors of the Company are responsible for the release of this
announcement.

 

For further information, please contact:

 

 OptiBiotix Health plc                        www.optibiotix.com (http://www.optibiotix.com/)
 Neil Davidson, Chairman  Contact via Walbrook below
 Stephen O'Hara, Chief Executive

 Peterhouse Capital Limited (Broker)          Tel: 020 7220 9797
 Duncan Vasey / Lucy Williams

 Walbrook PR Ltd                              Mob: 07876 741 001
 Anna Dunphy

 

About OptiBiotix - www.optibiotix.com (http://www.optibiotix.com/)

OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings
science to the development of compounds which modify the human microbiome -
the collective genome of the microbes in the body - in order to prevent and
manage human disease and promote wellness.

 

OptiBiotix has an extensive R&D programme working with leading academics
in the development of microbial strains, compounds, and formulations which are
used as active ingredients and supplements. More than twenty international
food and healthcare supplement companies have signed agreements with
OptiBiotix to incorporate their human microbiome modulators into a wide range
of food products and drinks.

 

OptiBiotix is also developing its own range of consumer supplements and health
products. The Company's current areas of focus include obesity, cardiovascular
health, and diabetes.

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements.
These forward-looking statements are not historical facts but rather are based
on the Company's current expectations, estimates, and projections about its
industry; its beliefs; and assumptions. Words such as 'anticipates,'
'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar
expressions are intended to identify forward-looking statements. These
statements are not guarantees of future performance and are subject to known
and unknown risks, uncertainties, and other factors, some of which are beyond
the Company's control, are difficult to predict, and could cause actual
results to differ materially from those expressed or forecasted in the
forward-looking statements. The Company cautions security holders and
prospective security holders not to place undue reliance on these
forward-looking statements, which reflect the view of the Company only as of
the date of this announcement. The forward-looking statements made in this
announcement relate only to events as of the date on which the statements are
made. The Company will not undertake any obligation to release publicly any
revisions or updates to these forward-looking statements to reflect events,
circumstances, or unanticipated events occurring after the date of this
announcement except as required by law or by any appropriate regulatory
authority.

 

 

This communication is a "Reach" announcement. Reach is a non-regulatory news
service. By using this service an issuer is confirming that the information
contained in this announcement is of a non-regulatory nature. Information
required to be notified under the AIM Rules for Companies, Market Abuse
Regulation or other regulation would be disseminated as an RNS regulatory
announcement and not on RNS Reach.

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUKANRSRUSUAR